Curriculum Vitae

Personal information

Sylvie Benchetrit

Work experience

- October 2022 - present: **PDCO Vice-Chair**
- 2013 - present: PDCO **Delegate** FR
- 2011 - 2012: PDCO Alternate FR

- 2007- present: Agence Nationale de Sécurité des Médicaments et des produits de santé (ANSM, Innovation and Europe Department)
  - Senior clinical assessor for PIPs, since the beginning of the PDCO
  - 2011 - present: ANSM **Paediatric Referent**, contribution to all medicines'assessments and general subjects, including external topics (national entities, students' training, forums). Previously manager of the paediatric unit.
  - Responsible of the permanent **paediatric expert group** of clinicians, pharmacists and patient representatives.

Education and training

- 1987 - 1993: **Doctor in Pharmacy**, PhD, Paris V
  - Doctorate thesis: Latin America Drug Market
- 2005 - 2007: **Master research in Epidemiology and Public Health,** DEA, Paris V medical school - Institut Pasteur
  - Thesis: heat wave and drugs' consumption, 2006 (Inserm, ansm Safety Department)

- 2021: Modelling and Simulation population pharmacology DESU, Aix-Marseille
- 2012- 2013: Medicines in immunology: vaccines, antibodies, cytokines, cellular and genetic therapies, DU, Paris V Hôpital G. Pompidou
- 2009 - 2010: Methodology, clinical trials interpretation, DIU, Lyon I
- 1992 - 1993: Marketing, DU, Paris V

Additional information

Publications

- Contribution as a paediatric expert in different recommendations:

EMA Guidelines: on Registries and RWE ; for the treatment of Duchenne and Becker muscular dystrophy, Epileptic disorders, neonatal seizures ; Paediatric Gaucher disease: a strategic collaborative approach from EMA and FDA ; Good Pharmacovigilance Practice Specific Considerations IV: Paediatric Population.

- Publications:

Joint HTA-regulatory perspectives on understanding evidence challenges, managing uncertainties and exploring potential solutions, EMA. 2025

Evidence generation throughout paediatric medicines life cycle: findings from collaborative work between European Medicines Agency (EMA) and EUnetHTA on use of extrapolation. Br J Pharmacol. 2025

Real-World Evidence to Support EU Regulatory Decision Making-Results From a Pilot of Regulatory Use Cases. Clin Pharmacol Ther. 2024

European regulatory strategy for supporting childhood cancer therapy developments. Eur J Cancer. 2022

Projects

Memberships

- 2023 - present: European Specialised Expert Communities of EMA of methodology, neurology and haematology
- 2022 - present: "Haut Conseil de Santé Publique - commission santé des enfants et des jeunes (HCSP-SEJAP)": High Council of Public Health, ministry of health FR: reports and advice to improve public health

Other Relevant Information

1987-92: President of the students in Paris for the Non-profit organization Pharmaciens sans Frontières (PSF)

1992-1993: Agence Française du Sang (French Blood Agency at its creation with the Ministry of Health)

1993 - 2005: Pharmaceutical industries (areas of marketing and production), Strategy and Communication